79560-17-1 Usage
Description
4-(3,4-Dichlorophenyl)-4-phenylbut-3-enoic Acid is an organic compound characterized by its chemical structure that features a butenoic acid backbone with a 3,4-dichlorophenyl and a phenyl group attached to the 4th carbon. This molecule is known for its potential applications in various industries due to its unique chemical properties.
Uses
Used in Pharmaceutical Industry:
4-(3,4-Dichlorophenyl)-4-phenylbut-3-enoic Acid is used as a reactant for the preparation of trans-1-amino-4-aryltetralin derivatives, which are nontricyclic antidepressant agents. 4-(3,4-Dichlorophenyl)-4-phenylbut-3-enoic Acid plays a crucial role in the synthesis of these antidepressants, contributing to the development of novel treatments for depression.
Check Digit Verification of cas no
The CAS Registry Mumber 79560-17-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,9,5,6 and 0 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 79560-17:
(7*7)+(6*9)+(5*5)+(4*6)+(3*0)+(2*1)+(1*7)=161
161 % 10 = 1
So 79560-17-1 is a valid CAS Registry Number.
79560-17-1Relevant articles and documents
Nontricyclic Antidepressant Agents Derived from cis- and trans-1-Amino-4-aryltetralins
Welch, Willard M.,Kraska, Allen R.,Sarges, Reinhard,Koe, B. Kenneth
, p. 1508 - 1515 (2007/10/02)
The need for drugs that lack the obtrusive and limiting side effects of the tricyclic antidepressants has prompted the search for agents with greatly enhanced selectivity for specific mechanisms believed to be essential for antidepressant efficacy.The potential role of derangements of 5-HT pathways in the etiology of depression has long been suspected and has given impetus to the development of newer compounds that accentuate inhibition of serotonin reuptake.This paper presents structure-activity relationship for a series of cis-1-amino-4-(substituted-aryl)tetralins, which are surprisingly potent and selective inhibitors of serotonin uptake in in vitro models.These compounds are pharmacologically distinct from corresponding members of the trans series, which also potently block uptake of dopamine and norepinephrine.The activity in both cis and trans series is stereospecific, being restricted to the cis-(1S,4S) and the trans-(1R,4S) enantiomers.